Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
In August 2024, Metsera, a newly launched clinical-stage biopharmaceutical company, emerged with a significant US$ 290 million in funding to develop innovative treatments for obesity and metabolic diseases, particularly focusing on GLP-1 receptor agonists
Semaglutide addresses two key factors in weight control: appetite and blood sugar regulation
Because the Part D portion of BALANCE has been delayed (more on that below), the Bridge was extended through the end of 2027 and is now the main pathway for Medicare beneficiaries seeking GLP-1 coverage for weight loss
Our firm's commitment to sustainability informs our operations, governance, risk management, diversity efforts, philanthropy and research
Summary The PPP plays a critical role in type 2 diabetes and cancer
US$ 23.83
US$ 23.96
US$ 22.43
US$ 22.05
